Navigation Links
Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
Date:7/28/2008

Financing will advance the company's clinical development programs and

CombiPlex(TM) technology platform

PRINCETON, N.J., July 28 /PRNewswire-FirstCall/ -- Celator Pharmaceuticals, a privately held pharmaceutical company developing novel products based on proven combinations of chemotherapeutic drugs, today announced that it raised in excess of $22.5 million in a Series C private equity financing.

All Series B investors participated in the financing and included; Domain Associates, Ventures West, Quaker BioVentures, TL Ventures, GrowthWorks Capital, and BDC Capital.

The proceeds will be used to fund Phase 2 studies of CPX-351 (a liposomal formulation of cytarabine:daunorubicin) in patients with acute myeloid leukemia. The company expects to start enrolling patients in a Phase 2 study of CPX-351 in newly diagnosed, elderly patients with AML before the end of 2008. Celator will continue to develop other CombiPlex(TM) products from its pipeline alone or in collaborations with pharmaceutical partners.

"This financing reflects the strong, continued support of our investors both in the company and our products," said Scott Jackson, chief executive officer of Celator Pharmaceuticals. "Our goal is to extend and enhance the lives of people with cancer. As a result, we have developed an oncology product pipeline that has significant commercial potential. These funds will allow us to conduct additional clinical trials and generate data that we believe will enable strategic partnerships with leading biotech and pharmaceutical companies."

Celator reported encouraging interim Phase 1 data with CPX-351 in December 2007 where complete remissions were obtained in patients with advanced leukemia. The company plans to submit additional CPX-351 pre-clinical and clinical data to this year's American Society of Hematology (ASH) meeting in December. In addition, positive Phase 2 clinical study results were reported for CPX-1
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
2. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
3. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Creekridge Capital, an independent vendor-focused finance ... so far in 2014 to their portfolio of ... from both the healthcare and technology industries. They ... multi-national companies. Each of these new vendors take ... including: standard leasing products, subscription solutions, a dedicated ...
(Date:7/23/2014)... -- When it comes to welcoming our new robot overlords, InformationWeek ... the red carpet. Healthcare is one of the ... into our human sphere. With healthcare concerns top of mind ... apply new technologies to help with old problems. That,s where ... expected to increase from $1.7 billion now to $3.7 billion ...
(Date:7/23/2014)... 2014  Researchers from the North American Menopause Society ... calcium levels too high, 1 putting women at ... Women close to menopause are commonly told to ... diseases such as osteoporosis, to which they are particularly ... how much calcium they typically get through their food ...
Breaking Medicine Technology:Creekridge Capital Signs Several New Vendor Partners 2Women Taking Too Much Calcium Create Health Risk 2
... announces that a new market research report is ... Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and ... http://www.reportlinker.com/p0479828/Juvenile-Rheumatoid-Arthritis-JRA-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html Juvenile Rheumatoid Arthritis (JRA) ... 2017 Summary ...
... announces that a new market research report is ... Cancer Therapy Area Pipeline Report ... Therapy Area Pipeline Report contains detailed information on ... insight into the pipeline status of pancreatic cancer ...
Cached Medicine Technology:Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Pancreatic Cancer Therapy Area Pipeline Report 2Reportlinker Adds Pancreatic Cancer Therapy Area Pipeline Report 3
(Date:7/23/2014)... and young adults living near Sellafield or Dounreay since ... developing cancer according to research published in the ... from the Childhood Cancer Research Group at the University ... between 1963 and 2006 among those who were under ... No difference was found in cancer incidence from 1991-2006 ...
(Date:7/23/2014)... 2014 A new study has uncovered ... ( http://www.injurybeacon.com/power-morcellator/ ) during minimally invasive hysterectomies can ... woman’s body, Bernstein Liebhard LLP reports. The research, which ... the American Medical Association, looked at 36,000 women who ... U.S. hospitals from 2006 to 2012. Ninety-nine of the ...
(Date:7/23/2014)... patients if a suspicious skin lesion is painful or ... likely to be cancerous, according to a new study ... of Dermatology at Temple University School of Medicine. , ... on July 23, 2014, found that nearly 36. 9 ... while 28.2 percent involve pain. Non-melanoma skin cancers ...
(Date:7/23/2014)... -- Painful or itchy skin lesions could be a ... sometimes have multiple lesions that are suspicious looking, and ... concerns for non-melanoma skin cancers," study author Dr. Gil ... Medicine, said in a Temple University Health System news ... 268 patients who were confirmed to have skin cancer ...
(Date:7/23/2014)... Rich Dad® Education, a leader in financial education, is ... to support Habit for Humanity of Lee and Hendry Counties. ... be donated to Habitat for Humanity. Additionally, all the items ... Habitat for Humanity ReStore thrift store located at 31 Willis ... the highlights of the yard sale was a visit from ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2Health News:Painful, Itchy Patches Could Be Sign of Skin Cancer 2Health News:Rich Dad Education Charity Yard Sale Raises Over $650 for Habitat for Humanity of Lee and Hendry Counties 2
... its smoking ban to entertainment outlets including pubs, nightclubs ... cut tobacco-related diseases. ,The ban will ... city-state which already has some of the toughest anti-smoking ... restrict smoking in entertainment outlets is a natural extension ...
... opportunity for superstition and marketing to come together: starry-eyed couples ... Earth concerts as well as the proclamation of the world's ... 7 has a magic sacred side and the reputation of ... bring an extra dose of good fortune. ,"Number ...
... Brahmachari and Dr. MRS Rao will be jointly awarded the ... 2005 for their outstanding contribution in the field of bio-medical ... one lakh. ,Besides, the Indian Council of Medical ... country to be honoured for their outstanding contributions in research ...
... prospective study suggests that ovarian germ cell tumour ... may retain their menstrual function and reproductive ... the Journal of Clinical Oncology, also found that ... more likely than their healthy counterparts to be ...
... a cure for smelly and pongy feet - special socks made ... eco-friendly sock to go on general sale, and experts have forecasted ... to take place in the world of clothing. ... of the silky material, which is softer, more durable and absorbent ...
... a slew of studies have highlighted the adverse effects of ... hours of gaming can actually be good for children. ... competing against each other give children a chance to learn ... and other races. ,The study by researchers from ...
Cached Medicine News:Health News:Singapore Extends Smoking Ban to Pubs, Nightclubs 2Health News:A Lucky Number? 7/7/07 2Health News:A Lucky Number? 7/7/07 3Health News:Survivors of Rare Ovarian Cancer may Retain Menstrual Function and Reproductive Ability 2Health News:Survivors of Rare Ovarian Cancer may Retain Menstrual Function and Reproductive Ability 3Health News:Exposure to Computer Games can Be 'good' for Kids, Says New Study 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: